These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329 [TBL] [Abstract][Full Text] [Related]
32. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Pugh TJ; Weeraratne SD; Archer TC; Pomeranz Krummel DA; Auclair D; Bochicchio J; Carneiro MO; Carter SL; Cibulskis K; Erlich RL; Greulich H; Lawrence MS; Lennon NJ; McKenna A; Meldrim J; Ramos AH; Ross MG; Russ C; Shefler E; Sivachenko A; Sogoloff B; Stojanov P; Tamayo P; Mesirov JP; Amani V; Teider N; Sengupta S; Francois JP; Northcott PA; Taylor MD; Yu F; Crabtree GR; Kautzman AG; Gabriel SB; Getz G; Jäger N; Jones DT; Lichter P; Pfister SM; Roberts TM; Meyerson M; Pomeroy SL; Cho YJ Nature; 2012 Aug; 488(7409):106-10. PubMed ID: 22820256 [TBL] [Abstract][Full Text] [Related]
33. Reduced hydroxymethylation characterizes medulloblastoma while TET and IDH genes are differentially expressed within molecular subgroups. Bezerra Salomão K; Cruzeiro GAV; Bonfim-Silva R; Geron L; Ramalho F; Pinto Saggioro F; Serafini LN; Antunes Moreno D; de Paula Queiroz RG; Dos Santos Aguiar S; Cardinalli I; Yunes JA; Brandalise SR; Brassesco MS; Scrideli CA; Gonzaga Tone L J Neurooncol; 2018 Aug; 139(1):33-42. PubMed ID: 29582271 [TBL] [Abstract][Full Text] [Related]
34. Mutation and expression analysis in medulloblastoma yields prognostic variants and a putative mechanism of disease for i17q tumors. Bien-Willner GA; Mitra RD Acta Neuropathol Commun; 2014 Jul; 2():74. PubMed ID: 25030029 [TBL] [Abstract][Full Text] [Related]
35. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951 [TBL] [Abstract][Full Text] [Related]
36. Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma. Langdon JA; Lamont JM; Scott DK; Dyer S; Prebble E; Bown N; Grundy RG; Ellison DW; Clifford SC Genes Chromosomes Cancer; 2006 Jan; 45(1):47-60. PubMed ID: 16149064 [TBL] [Abstract][Full Text] [Related]
37. Dissecting the genomic complexity underlying medulloblastoma. Jones DT; Jäger N; Kool M; Zichner T; Hutter B; Sultan M; Cho YJ; Pugh TJ; Hovestadt V; Stütz AM; Rausch T; Warnatz HJ; Ryzhova M; Bender S; Sturm D; Pleier S; Cin H; Pfaff E; Sieber L; Wittmann A; Remke M; Witt H; Hutter S; Tzaridis T; Weischenfeldt J; Raeder B; Avci M; Amstislavskiy V; Zapatka M; Weber UD; Wang Q; Lasitschka B; Bartholomae CC; Schmidt M; von Kalle C; Ast V; Lawerenz C; Eils J; Kabbe R; Benes V; van Sluis P; Koster J; Volckmann R; Shih D; Betts MJ; Russell RB; Coco S; Tonini GP; Schüller U; Hans V; Graf N; Kim YJ; Monoranu C; Roggendorf W; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; von Deimling A; Witt O; Maass E; Rössler J; Ebinger M; Schuhmann MU; Frühwald MC; Hasselblatt M; Jabado N; Rutkowski S; von Bueren AO; Williamson D; Clifford SC; McCabe MG; Collins VP; Wolf S; Wiemann S; Lehrach H; Brors B; Scheurlen W; Felsberg J; Reifenberger G; Northcott PA; Taylor MD; Meyerson M; Pomeroy SL; Yaspo ML; Korbel JO; Korshunov A; Eils R; Pfister SM; Lichter P Nature; 2012 Aug; 488(7409):100-5. PubMed ID: 22832583 [TBL] [Abstract][Full Text] [Related]
38. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851 [TBL] [Abstract][Full Text] [Related]
39. Molecular subgroups of adult medulloblastoma: a long-term single-institution study. Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407 [TBL] [Abstract][Full Text] [Related]
40. Clinical and mutational profiles of adult medulloblastoma groups. Wong GC; Li KK; Wang WW; Liu AP; Huang QJ; Chan AK; Poon MF; Chung NY; Wong QH; Chen H; Chan DTM; Liu XZ; Mao Y; Zhang ZY; Shi ZF; Ng HK Acta Neuropathol Commun; 2020 Nov; 8(1):191. PubMed ID: 33172502 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]